FDA approves cervical cancer DNA test

Share this article:

Test specifically identifies HPV types 16 and 18, as well as detecting 12 other types of high-risk HPVs.

FDA approves weekly GLP-1 agonist for type 2 diabetes
FDA approves weekly GLP-1 agonist for type 2 diabetes

HealthDay News -- The FDA has approved the first human papillomavirus (HPV) DNA test for women aged 25 years and older that can be used to assess the need for a woman to undergo additional diagnostic testing for cervical cancer.

The cobas HPV Test uses cervical cell samples to specifically identify HPV  types 16 and 18, the two types responsible for approximately 70% of cervical cancers, and also detects 12 other types of high-risk HPVs at the same time.

In addition, the test can provide information about a patient's future risk for developing cervical cancer.

Women who test positive for HPV 16 or 18 should have a colposcopy, and women testing positive for at least one of the 12 other high-risk HPV types should have a Pap test to determine the need for a colposcopy.

Other information should be used by health care professionals in conjunction with the cobas HPV Test results, including the patient's screening history and risk factors, as well as current professional guidelines.

The cobas HPV Test's safety and effectiveness were evaluated in a study of more than 40,000 women 25 years and older who underwent routine cervical exams. Women who had a positive Pap test or whose cervical cells screened positive for HPV, as well as a subset of women whose Pap and HPV tests were both negative, underwent a colposcopy and cervical tissue biopsy

The biopsy results were compared to the Pap and cobas HPV Test results. Results from this study, including three-year follow-up data indicated that the cobas HPV Test was safe and effective for use as a primary screening tool for cervical cancer.

The cobas HPV Test is manufactured by Roche Molecular Systems Inc., based in Pleasanton, Calif.

More Information

Share this article:
You must be a registered member of Clinical Advisor to post a comment.

More in Web Exclusives

Empagliflozin approved to treat diabetes

Empagliflozin approved to treat diabetes

Pivotal trials showed that empagliflozin improved hemoglobin A1c levels compared with placebo.

Presence, pain intensity, itch may be a sign of skin cancer

Presence, pain intensity, itch may be a sign ...

The prevalence of itch was 36.9%, and the prevalence of pain was 28.2% across all skin cancer, but these symptoms were mainly absent in melanomas

Travel warning issued after Ebola outbreak worsens in West Africa

Travel warning issued after Ebola outbreak worsens in ...

Agency also plans to send 50 more experts to the affected countries.